Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmation) program will support the development of the product and the clinical validation of the AI system in a multi-center prospective study.